 The FDA has granted Fast Track designation to Sutro Biopharma Incs NASDAQ: STRO STRO-002 for ovarian cancer. The designation covers platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients who have received one to three prior lines of systemic therapy. 